Coherus Oncology (CHRS) Asset Writedowns and Impairment (2015 - 2025)

Coherus Oncology (CHRS) has 9 years of Asset Writedowns and Impairment data on file, last reported at $12.5 million in Q4 2025.

• For the quarter ending Q4 2025, Asset Writedowns and Impairment rose 68.96% year-over-year to $12.5 million; the trailing twelve-month figure through Dec 2025 stood at $20.3 million (up 43.71% YoY), and the FY2025 full-year result was $14.1 million, changed 0.3% from the prior year.
• Asset Writedowns and Impairment climbed to $12.5 million in Q4 2025, from $500000.0 in the prior quarter.
• In the past five years, Asset Writedowns and Impairment ranged from a high of $48.2 million in Q4 2023 to a low of -$347000.0 in Q2 2023.
• A 5-year average of $9.6 million and a median of $3.2 million in 2023 frame the typical range for Asset Writedowns and Impairment.
• Across the five-year window, Asset Writedowns and Impairment tumbled 94.33% in 2023 and jumped 109.81% in 2024, its largest moves.
• Tracing CHRS's Asset Writedowns and Impairment over 5 years: stood at -$59000.0 in 2021, then surged by 44167.8% to $26.0 million in 2022, then soared by 85.48% to $48.2 million in 2023, then sank by 84.72% to $7.4 million in 2024, then surged by 68.96% to $12.5 million in 2025.
• Business Quant data shows CHRS's Asset Writedowns and Impairment at $12.5 million in Q4 2025, $500000.0 in Q3 2025, and $7.4 million in Q4 2024.